What are the safety advantages of besudil compared with existing cGVHD drugs?

Belumosudil mesylate tablets (Belumosudil) is a selective ROCK2 inhibitor approved for the treatment of chronic graft-versus-host disease (cGVHD) that has failed previous treatments. Its safety performance has become the focus of clinical attention. Compared with traditional drugs for treating cGVHD, such as systemic glucocorticoids, calcineurin inhibitors (such as cyclosporine, tacrolimus) or IL-2 pathway inhibitors, besudil exhibits a milder and specific immune regulation method, giving it certain advantages in terms of safety. Existing treatment options often bring serious infection risks, metabolic disorders or multi-system side effects related to immunosuppression. However, because Besudil targets the ROCK2 pathway, it is more inclined to restore the balance of T cell subsets and suppress pro-inflammatory responses during the immune regulation process, rather than comprehensively suppressing the immune system.

In addition, the oral administration route of besudil makes it more convenient and avoids adverse events such as injection site reactions or infusion reactions associated with intravenous administration. In actual use, most of the adverse reactions such as gastrointestinal discomfort and liver enzyme elevation are reversible and mild to moderate, and a few patients need to permanently discontinue the drug due to drug-related toxicity. This is different from the long-term use of traditional immunosuppressive drugs that require close monitoring of renal function, electrolytes and bone marrow suppression risks. Although besudil is not completely free of side effects, its specific mechanism and overall good tolerance make it more controllable in the long-term management of cGVHD, and also reduces the incidence of serious complications such as secondary infection and tissue and organ toxicity.

Therefore, in the currentcGVHD treatment, besudil provides a treatment option with a unique mechanism and better safety, especially suitable for patients who are resistant or intolerant to traditional immunosuppressive treatments.

Reference: https://www.drugs.com/pro/rezurock.html